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Abstract
Background: Amyloid precursor protein (APP) is a ubiquitously expressed cell surface protein reported to be
involved in mediating cell-cell or cell-matrix interactions. Prior work has demonstrated that APP co-localizes with
b1 integrin in different cell types.
Methods: In an effort to determine the function of APP on monocytic lineage cells, in particular, the human
monocyte cell line, THP-1, was used to assess the role of APP during adhesion to the extracelluar matrix
component type I collagen.
Results: Pull-down assays demonstrated that THP-1 adhesion to collagen stimulated a tyrosine kinase-associated
signaling response which included subsequent phosphorylation of p38 MAP kinase and increased association of
APP with a2b1 integrin, specifically. In addition, cell adhesion was dependent upon APP expression since APP
siRNA knockdown attenuated THP-1 adhesion to collagen compared to mock transfected controls. One
consequence of the tyrosine kinase-dependent signaling response was increased secretion of interleukin-1b (IL-1b)
and Ab1-40 but not the Ab1-42 fragment of APP. Increased secretion of IL-1b was dependent upon p38 MAP
kinase activity while Ab1-40 secretion required Src family kinase activity since the specific p38 inhibitor, SB202190,
and the Src family kinase inhibitor, PP2, attenuated IL-1b and Ab1-40 secretion, respectively.
Conclusions: These data demonstrate that APP is involved in classic integrin-dependent tyrosine kinase-associated
adhesion and activation of peripheral monocytic cells. Moreover, divergent APP-dependent signaling is required for
increased secretion of both IL-1b and Ab1-40 as a component of the adhesion-dependent change in phenotype.
This suggests that APP may have a broad role in not only mediating cell-matrix adhesion but also in the function
of peripheral immune cells.
Background
The progressive accumulation of extracellular beta amy-
loid-containing plaques is a cardinal feature of Alzhei-
mer’s disease (AD) pathology. The beta amyloid (Ab)
peptide is generated through sequential cleavage of the
amyloid precursor protein (APP) by b-a n dg-secretase.
Altered proteolysis of APP due to missense mutations in
the APP gene results in increased production of Ab and
increased accumulation of plaques [1-3]. APP is a ubi-
quitously expressed integral membrane protein with a
relatively undefined function separate from generating
Ab [4]. Several data support a role for APP in adhesion
including evidence that APP co-localizes with b1i n t e g -
rins in both neurons and monocytes as well as evidence
that APP binds directly to type I collagen and other
extracellular matrix (ECM) molecules [5-8].
Adhesion of monocytes to vascular endothelium is a
highly regulated, necessary step in transendothelial
migration that occurs constitutively but also during a
variety of conditions including peripheral inflammation,
infection, atherosclerosis, neurodegenerative disease, and
injury [9-14]. Monocyte adhesion to the endothelium
initiates changes in their gene expression important in
differentiation and extravasation [12]. During diapedesis,
monocytes also closely interact with extracellular matrix
components, in part through integrin receptor
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towards macrophage differentiation [15-17]. Integrin-
mediated activation of monocytes is characterized by a
tyrosine-kinase dependent proinflammatory signaling
response and release of multiple proinflammatory mole-
cules [7,18-21]. Interestingly, in vitro exposure of
endothelial cells to Ab1-40 up-regulates endothelial
adhesion molecule expression and monocytic adhesion
to these cells, thus facilitating the transmigration pro-
cess [22].
Plasma levels of Ab have debatable implications with
regard to increased risk for cerebral amyloid angiopathy
[23]. Ab1-40, rather than Ab1-42, appears to be the
dominant component in the vascular depositions
[24,25]. While Ab1-42 levels and deposition in the brain
are correlated with the incidence of AD, it has been
demonstrated that increased levels of plasma Ab1-40
correlate with an increased incidence of dementia [26].
Platelets are a known source of peripheral Ab produc-
tion and recent data shows an increased b-secretase
activity in platelets from patients with AD [27,28]. How-
ever, monocytes are another peripheral source of Ab
and interestingly it has been shown that adhesion stimu-
lates an increased release of Ab1-40 from these cells
[29].
This study aims to further characterize the role of
APP in adhesion-mediated activation of monocytes. In
addition, we propose that b1 integrin ligation of mono-
cytes by an endogenous ligand such as type I collagen is
an important mechanism through which peripheral Ab
is released, and this may have implications in pathologi-
cal accumulations of Ab in the brain parenchyma as
well as in the vasculature.
Methods
Materials
The 4G10 monoclonal anti-phosphotyrosine antibody
was purchased from Upstate Biotechnology (Lake Placid,
NY). Anti-b-Amyloid Precursor Protein polyclonal anti-
body was from Zymed Laboratories (San Francisco, CA).
Anti-phospho-p38, anti-p38, anti-phospho-JNK, anti-
JNK were from Cell Signaling (Beverly, MA). Anti-a2
integrin antibody, anti-a1 integrin antibody, anti-b1
integrin antibody, anti-phospho-ERK, anti-ERK2 anti-
body, and Protein A/G PLUS-Agarose beads were from
Santa Cruz Biotechnology (Santa Cruz, CA). The 22C11
anti-APP monoclonal antibody, gamma-secretase inhibi-
tor, and beta-secretase inhibitor were from Calbiochem
(La Jolla, CA). Anti-mouse (goat), anti-rabbit (donkey),
and anti-goat (donkey) horseradish peroxidase (HRP)
conjugated secondary antibodies were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA). APP siRNA
(siGene, SMARTpool Plus) was obtained from Dharma-
con (Lafayette, CO). Type I collagen was derived from
rat tail following a standard protocol. All other materials
not specified were purchased from Sigma (St. Louis,
MO).
Tissue culture
THP-1 cells are a monocytic cell line derived from per-
ipheral blood of a human with acute monocytic leuke-
mia commercially available from the American Type
Culture Collection (Manassas, VA). THP-1 cells were
grown in RPMI-1640 (Gibco RBL, Rockville, MD) con-
taining 10% heat inactivated fetal bovine serum (FBS)
(U.S. Biotechnologies Inc., Parkerford, PA), 5 mM
Hepes, and 1.5 μg/mL pen/strep/neomycin.
Cell stimulation
THP-1 monocytes were removed from normal growth
medium into serum-free RPMI and incubated at 37°C
for fifteen minutes prior to stimulation. Tissue culture
wells were coated with type I rat tail collagen and
allowed to dry in a laminar flow hood. THP-1 cells were
added to either low-adhesion tissue culture plastic alone
or to wells coated with type I collagen at a density of
2×1 0
6 cells/mL. Cells were stimulated for either
30 min, 24 hours, or 48 hours. In inhibition studies,
cells were incubated at 37°C for 30 minutes with inhibi-
tors before stimulation.
Western blotting
Ice cold RIPA buffer (20 mM Tris pH 7.4, 150 mM
NaCl, 1 mM Na3VO4,1 0m MN a F ,1m ME D T A ,1
mM EGTA, 0.2 mM PMSF, 1% Triton, 0.1% SDS, 0.5%
deoxycholate) was used to lyse cells. Cell lysates were
sonicated and centrifuged (14,000 RPM, 4°C, 10 min) to
remove insoluble material. Protein concentrations were
quantitated by the method of Bradford [30]. Proteins
were resolved by 7% or 10% SDS-PAGE and transferred
to PVDF membranes for Western blotting. Western
blots were blocked in TBS-T (10 mM Tris, pH 7.4,
100 mM NaCl, and 0.1% Tween 20) containing 3% BSA
for 15 minutes and then incubated overnight at 4°C in
primary antibodies. Blots were washed three times in
TBS-T, followed by incubation for one hour with HRP
conjugated secondary antibodies in TBS-T containing 5%
nonfat dried milk. The blots were washed three times in
TBS-T followed by detection with enhanced chemilumi-
nescence (Pierce, Rockford, IL). In some instances, blots
were stripped in 0.2 N NaOH, 5 minutes, 25°C.
Immunoprecipitation
For co-immunoprecipitation, cells were lysed in ice cold
Triton lysis buffer (20 mM Tris pH 7.4, 150 mM NaCl,
1m MN a 3VO4,1 0m MN a F ,1m ME D T A ,1m M
E G T A ,0 . 2m MP M S F ,1 %T r i t o n ) .L y s a t e sw e r ev o r -
texed then incubated on ice for 15 minutes followed by
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to remove insoluble material. Primary antibody (1 μg/mg
protein) was added and incubated 2 hours at 4°C. Protein
A/G beads (35 μl) were added and incubated 2 hours at
4°C. Beads were washed three times with lysis buffer and
immunoprecipitates were resolved and Western blotted as
described above.
Kinase and secretase Inhibition
4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo [3,4-d]
pyrimidine (PP2) was purchased from Alexis Biochem-
icals (San Diego, CA). PP2 is a small-molecule inhibitor
specific for Src-family kinases believed to be a mixed
competitive inhibitor vis-à-vis the substrate [31]. The
cell permeable pyridinyl imidazole compound,
SB202190, inhibits p38 kinase activity through competi-
tion with ATP binding (Calbiochem) [32]. The gamma-
secretase inhibitor, Z-Leu-Leu-Nle-CHO, is a cell
permeable synthetic tripeptide aldehyde inhibitor of
gamma secretase activity (Calbiochem) [33]. The beta
secretase inhibitor, Z-VLL-CHO; N-Benzyloxycarbonyl-
val-leu-leucinal is a cell permeable, reversible inhibitor
(Calbiochem) [34].
Adhesion assay
THP-1 cells were loaded with calcein-AM (Molecular
Probes, Eugene, OR) by incubating at 1 × 10
6 cells/mL
in serum-free RPMI 1640 medium containing 5 μg/mL
calcein-AM for 30 min at 37°C. Cells were washed three
times with medium and resuspended at a plating density
of 1 × 10
6 cells/mL. 50 μl aliquots were added to a 96-
well plate coated with collagen and incubated at 37°C
and 5% CO2 for 45 min. Total cell number per well was
then assessed by reading the plates at an excitation
wavelength of 485 nm and an emission wavelength of
538 nm prior to washing the wells. Plates were then
washed three times with PBS and fluorescence of
adhered cells was determined at an excitation wavelength
of 485 nm and an emission wavelength of 538 nm. The
fluorescence value of adhered cells was then normalized
according to the original cell number value.
Enzyme linked-immuno-sorbent assay (ELISA)
Media was collected from THP-1 cells following 24 hour
or 48 hour stimulation. Media was centrifuged for clari-
fication (14,000 × g, 2 min, 25°C) prior to analysis.
Levels of human interleukin-1b,A b1-42, and Ab1-40 in
the media were determined using commercially available
ELISA kits (Immuno-Biological Laboratories Inc. Min-
neapolis, MN), according to the manufacturer’s protocol.
APP siRNA transfection
THP-1 cells were transfected with an individual
APP siRNA duplex (GCCTAAAGCTGATAAGAAG)
(Dharmacon, Lafayette, CO) (2 × 10
6 cells: 2 μgs i R N A )
using the appropriate Nucleofector program as
described by the manufacturer (Amaxa Inc., Gaithers-
burg, MD).
Results
In agreement with our previous studies [7], adhesion of
THP-1 monocytes to type I collagen stimulated an APP-
associated tyrosine kinase-dependent increase in protein
phosphotyrosine levels as well as increased levels of the
active, phosphorylated form of the p38 mitogen-acti-
vated protein kinase (MAPK) (Fig. 1). Our prior work
demonstrated the specificity of this response for p38
MAP kinases compared to ERK or JNK enzymes as well
as 30 minutes for the optimal stimulation time to
observe these changes [7]. Adhesion to collagen also sti-
mulated a decrease in full-length glycosylated APP pro-
tein levels suggesting that activation of a collagen
receptor on the monocytes stimulated cellular changes
that result in either altered secretase activity, increased
APP turnover, or impaired transport (Fig. 1). As
expected, APP expression was necessary for the stimu-
lated increase in protein phosphotyrosine and phos-
phorylated p38 levels since siRNA knockdown of APP
protein levels was sufficient to attenuate the adhesion-
stimulated increase in both (Fig. 1B). Since tyrosine
kinase activation is necessary for downstream activation
o ft h ep 3 8M A P Kp a t h w a ya sw e l la ss u b s e q u e n t
increases in proinflammatory protein levels [7], it was
next determined whether the adhesion-dependent
changes in APP processing were also dependent on this
signaling. To address this question, the Src kinase
family-specific inhibitor, PP2, and the p38-specific inhi-
bitor, SB202190, were used to pretreat THP-1 cells prior
to stimulation with collagen. Drug pretreatment, while
effective at attenuating the increase in protein phospho-
tyrosine levels and active, phosphorylated p38 levels,
was not sufficient to alter the adhesion-stimulated
decrease in full-length APP protein levels suggesting
that this change was independent of tyrosine kinase and
p38 MAPK activity (Fig. 1).
Previously, we demonstrated that collagen adhesion sti-
mulated formation of a multi-receptor complex including
APP and b1 integrin receptors in monocytes and this
recruitment of APP to b1 integrins was specific to col-
lagen compared to laminin, fibronectin, and poly-L-lysine
[7]. In order to better define this collagen-dependent, b1-
APP response and determine which a subunit was
involved, immunoprecipitation pull-down assays were
performed with and without collagen stimulation to iden-
tify specific a receptor recruitment. To increase the
probability of detecting APP-integrin receptor associa-
tion, monocytes were pre-stimulated overnight with LPS
which has been demonstrated to upregulate cell surface
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ment increased cell surface APP levels in the THP-1
monocytes while total protein levels remained the same
( F i g .2 C ) .A d d i t i o n a l l y ,a2 integrin protein levels also
increased upon LPS-stimulated activation of these cells
(Fig. 2B). Immunoprecipitation with anti-APP antibodies
verified that a2 integrin was recruited to a complex with
APP and the b1 subunit in contrast to a6o ra1i n t e g r i n
(Fig. 2A) confirming that a specific APP-b1i n t e g r i n
receptor complex was formed upon type I collagen inter-
action. Converse co-immunoprecipitatons using a2o rb1
antibodies confirmed that collagen adhesion stimulated
formation of a multi-receptor complex with APP and
a2b1 integrins (Fig. 2A).
Monocytes are capable of secreting numerous proin-
flammatory molecules upon activation, including Ab
[29,37]. Considering these data we hypothesized that
adhesion of monocytes to type I collagen would stimu-
late the release of Ab. To test this hypothesis, levels of
secreted Ab peptides in the media following monocytic
adhesion to collagen were quantitated by ELISA. Mono-
cytes were allowed to adhere to collagen for 48 hours to
ensure adequate time to achieve quantifiable levels of
Ab. Adhesion of monocytes to type I collagen stimu-
lated increased secretion of Ab1-40 and not Ab1-42
(Fig. 3). To determine if the increased Ab1-40 release
was dependent upon propagation of the tyrosine kinase-
dependent signaling or p38 MAPK activity, we again
u s e dt h et y r o s i n ek i n a s ei n h i b i t o r ,P P 2 ,o rt h ep 3 8
MAPK inhibitor, SB202190, to inhibit kinase activity in
the monocytes prior to and during adhesion. Either inhi-
bitor attenuated basal Ab1-40 secretion (Fig. 3A).
Figure 1 Adhesion of monocytes to collagen stimulated a tyrosine kinase-dependent signaling response and a tyrosine kinase-
independent decrease in full-length APP protein levels. A) THP-1 cells were either untreated or treated for 30 minutes with PP2 (5 μM) or
DMSO vehicle. Cells were plated on tissue culture plastic alone or on type I collagen. B) THP-1 cells were either not transfected or transfected
with individual APP siRNA duplexes. At 24 hours post-transfection, non-transfected cells were unstimulated (control) or stimulated by adhesion
to collagen, and transfected cells were stimulated by adhesion to collagen. Cells were plated on tissue culture plastic alone or on type I
collagen. Cells were lysed at 30 minutes in RIPA buffer, separated by 7% or 10% SDS-PAGE and Western blotted using anti-phosphotyrosine
antibody, 4G10, anti-phospho-p38 antibody, anti-p38 antibody (loading control), anti-APP antibody, and anti-ERK2 antibody (loading control).
Antibody binding was visualized by chemiluminescence.
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(25 ng/mL) for 24 hours prior to adhesion to collagen. Cells were plated on tissue culture plastic alone or on type I collagen. Cells were lysed at
30 minutes in 1% Triton X-100 buffer, and either a2 integrin, b1 integrin or APP was immunoprecipitated. Immunoprecipitates were resolved by
7% SDS-PAGE and Western blotted with anti-APP antibody, anti-a1 integrin antibody, anti-a6 integrin antibody, anti-a2 integrin antibody or
anti-b1 integrin antibody. B) THP-1 cells were either untreated (c) or treated with LPS (25 ng/mL) for 24 hours. Cells were lysed in RIPA buffer
separated by 7% SDS-PAGE and Western blotted using anti-a2 integrin antibody and anti-ERK2 antibody (loading control). C) THP-1 cells were
untreated (con) or treated for 24 hours with LPS (1 μg/ml). Cells were plated on coverslips and fixed with 4% paraformaldehyde. Cells were
immunostained with and without 1% triton permeabilization with anti-APP antibody. D) THP-1 cells were untreated (c) or treated for 24 hours
with LPS (1 μg/ml) or 10 μMA b. Cells were lysed in RIPA buffer separated by 7% SDS-PAGE and Western blotted using anti-APP antibody and
anti-ERK2 antibody (loading control). Antibody binding was visualized by chemiluminescence.
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normalize against the drug effects during collagen sti-
mulated secretion, only pretreatment with PP2 and not
SB202190 significantly decreased the release of Ab1-40
(Fig. 3A). This suggested that a divergence in tyrosine
kinase and p38 activation had occurred allowing each to
propagate unique phenotypic alteration. However, the
dependence of Ab1-40 secretion on Src family kinase
activity is in apparent contradiction with the earlier data
demonstrating that tyrosine kinase inhibition was not
sufficient to attenuate the collagen-stimulated decrease
in full-length APP. As added positive controls for the
experiment, cells were treated with either a b secretase
or g secretase inhibitor to verify that direct inhibition of
these secretases did indeed attenuate the release of Ab1-
40 (Fig. 3A).
In order to further define the APP-a2b1i n t e g r i ns t i -
mulated phenotype we continued examining adhesion-
dependent changes. Specific cytokine secretion, IL-1b,
was quantified to determine whether cytokine release
was also coupled to the the signaling response. Using
commercial ELISA reagents, IL-1b secreted into the
media was quantified following a 24 hour stimulation of
THP-1 cells with type I collagen in the absence or pre-
sence of secretase inhibitors or p38 MAP kinase or Src
family kinase inhibitors. In agreement with previous
data, there was a significant increase in release of IL-1b
from the monocytes following stimulation with type I
collagen (Fig. 4). To determine whether release of this
proinflammatory molecule was dependent on tyrosine
kinase or p38 MAP kinase activity, we used the kinase
inhibitors, PP2 and SB202190, respectively, to pretreat
the monocytes before and during stimulation with type I
collagen. While Ab1-40 release appeared to be down-
stream of Src family tyrosine kinase activity (Fig. 3), IL-
1b secretion was dependent upon an alternate pathway
as it was not affected by tyrosine kinase inhibition but
rather on activity of p38 kinase (Fig. 4). Curiously, b
secretase inhibition stimulated a robust, significant
increase in secreted IL-1b levels only in collagen stimu-
lated cultures and not control cells (Fig. 4).
Based upon the observation that APP, and possibly its
proteolytic fragments, is recruited to a signaling com-
plex with a2b1 integrin upon cellular interaction with
type I collagen and necessary for the complex signaling
response and secretory phenotype described above, it
was reasonable to assume that APP was necessary for
actual adhesion to collagen. As performed previously
[7], human APP siRNA transfection was used to
decrease APP expression in THP-1 cells (Fig 5A) for
comparison to mock transfected cells regarding their
ability to bind to type I collagen. Cells that had been
transfected to knock-down APP expression versus those
which were mock transfected demonstrated significantly
reduced adhesion to type I collagen as well as to poly-L-
lysine and tissue culture plastic alone (Fig. 5B). This
data further verified the role of APP as an adhesion
molecule in these cells.
Figure 3 Collagen stimulates a selective increase in Ab1-40 that is dependent on Src tyrosine kinase activity. THP-1 cells were either
untreated or treated for 30 min with SB202190 (100 nM), PP2 (5 μM), g-secretase inhibitor (10 μM), b-secretase inhibitor (5 μM) or DMSO vehicle.
Cells were plated on tissue culture plastic or collagen for 48 hours. Media was then collected and analyzed by human Ab1-40 and Ab1-42 ELISA.
Data were analyzed by unpaired ANOVA with Tukey’s post-test comparison and are expressed as mean +/- SD (* = p < 0.001 from control, ** =
p < 0.001 from collagen). SB202190 and PP2 treated collagen conditions were normalized to percent decrease due to drug only. Values are
representative of three independent experiments.
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Our data demonstrate that binding of THP-1 monocytes
to type I collagen stimulates a tyrosine kinase-dependent
proinflammatory signaling cascade that includes activa-
tion of p38 MAPK and subsequent increased IL-1b pro-
tein levels. In addition, monocyte adhesion to type I
collagen stimulates a decrease in full-length glycosylated
APP protein levels and a downstream increase in Ab1-
40 release. Furthermore, we have strengthened the exist-
ing data that suggest APP itself has a role in adhesion as
an APP siRNA-induced decrease in APP protein levels
resulted in a significant decrease in adhesion of mono-
cytes to type I collagen.
We previously demonstrated that b1 integrin ligation
on monocytes stimulates increased tyrosine kinase activ-
ity, recruitment of tyrosine kinases Lyn and Syk to APP,
and ultimately a reactive phenotype [7]. b1i n t e g r i n s
form heterodimeric receptors with different a subunits
and the specific combination of ab subunits dictates
both binding specificity and overall function of the
r e c e p t o r[ 3 8 ] .H e r ew ei d e n t i f yt h a ti ti st h ea2 subunit
that is recruited to the multi-receptor signaling complex
during the APP-b1 integrin associated signaling
response in monocytes [7]. Therefore, the a2b1 integrin
receptor, otherwise known as VLA-2 or CD49b, forms a
complex with APP to mediate the proinflammatory acti-
vation of THP-1 monocytes upon adhesion to an endo-
genous ligand, type I collagen. Importantly, both APP
and a2 integrin have collagen binding domains in their
extracellular regions supporting our observations.
The a2b1 integrin receptor has been identified as a
dual collagen/laminin receptor in several cell types [39].
It is a major collagen receptor expressed in keratino-
cytes, endothelial cells, fibroblasts as well as immune
cells. More interestingly, APP and its proteolytic pro-
ducts, have also been suggested to have a role in kerati-
nocyte [40,41], endothelial cell [42,43], fibroblast [44,45]
and immune cell [7,36,46,47] function. This correlation
Figure 4 Adhesion of monocytes to collagen stimulates a p38-dependent increase in IL-1b production. THP-1 cells were either untreated
or treated for 30 min with SB202190 (100 nM), PP2 (5 μM), g-secretase inhibitor (10 μM), b-secretase inhibitor (5 μM) or DMSO vehicle. Cells
were then plated on tissue culture plastic or collagen for 24 hours. Media were collected and analyzed by human interleukin-1b ELISA. Data
were analyzed by unpaired ANOVA with Tukey’s post-test comparison and are expressed as mean +/- SD (* = p < 0.001 from control, ** = p <
0.01 from collagen, *** = p < 0.001 from collagen). Values are representative of three independent experiments.
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associated function in monocytes but also suggests that
this biology will be relevant to a plethora of cell types. It
is known that platelets express the necessary secretases
to generate Ab peptides and are suggested to be the
major APP expressing cells in the blood [28,48,49].
Moreover, when they are stimulated, including by phy-
siologic agonists such as thrombin and collagen, they
are capable of secreting increased levels of various Ab
peptides [50,51]. In turn, platelets can also be stimulated
by Ab1-40 to increase their aggregation [52]. Therefore,
platelets have been identified as an important peripheral
source of Ab. Although our study has focused on mono-
cyte APP-a2b1 integrin dependent events, it is possible
that this biology will be relevant to platelets as well
since this receptor has a prominent role in platelet
aggregation.
Integrin-dependent monocyte activation, in particular,
involves a complex activation of tyrosine kinases [18]
and monocyte adhesion to this extracellular matrix pro-
tein stimulates increased cytokine and protease secretion
[53-55]. Moreover, it has already been confirmed that
a2b1 integrin can operate with other cell surface recep-
tors to mediate its range of effects on phenotype
[56,57]. Similarly, our data demonstrated a dependency
of a2b1 on APP expression for stimulating type I col-
lagen-dependent increases in tyrosine kinase-dependent
signaling and cellular adhesion. Therefore, monocytic
functions typically attributed to a2b1 integrin may be
altered in animals with decreased or mutant APP
expression. For example, studies using a2 knockout ani-
mals, have demonstrated an impaired innate immune
response[58]. It is intriguing to speculate that APP is
also involved in this biology and APP null animals will
share a similar dysfunction of innate immune cells.
Besides the APP-a2b1-mediated adhesion of mono-
cytes to type I collagen, we also observed a subsequent,
specific processing of APP. Specifically, secreted Ab1-42
levels remain unchanged after adhesion-mediated activa-
tion while secreted Ab1-40 levels increased. Interest-
ingly, Src family kinase activity regulated the collagen-
stimulated increase in secreted levels of Ab1-40 in spite
of the fact that it had no ability to attenuate the
decrease in full length glycosylated protein in this stimu-
lation. This implies that tyrosine kinase activity regulates
some point in the transport, turnover, secretion or
release of Ab1-40 rather than APP proteolysis. Not sur-
prisingly, Src family kinases have a diverse role in regu-
lating both uptake and release of membrane associated
proteins. For example, cell culture observations have
Figure 5 Adhesion of monocytes to collagen is dependent on expression of APP. THP-1 cells were either not transfected or transfected
with an individual APP siRNA duplex. A) At 24 hours post-transfection, cells were lysed with RIPA buffer, separated by 7% SDS-PAGE and
Western blotted with anti-APP antibody and anti-ERK2 antibody (loading control). B) At 24 hours post-transfection, transfected cells and non-
transfected cells were loaded with 5 μg/mL calcein-AM and plated on tissue culture plastic alone, poly-L-lysine, or type I collagen for 30 minutes.
Fluorescence from total cell number was read prior to washing the wells. Wells were then washed and fluorescence of adhered cells was
determined. Data were analyzed by unpaired ANOVA with Tukey’s post-test comparison and are expressed as mean +/- SD (*** = p < 0.001
from control, ** = p < 0.001 from mock transfected cells). Values are representative of three independent experiments.
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in positively regulating macropinocytosis [59], negatively
regulating kiss and run type exocytosis [60], and posi-
tively regulating calveolae release from the plasma mem-
brane through phosphorylation of calveolin-1 [61].
Although the focus of this work has been on Ab peptide
secretion as an endpoint of tyrosine kinase mediated
regulation, it is certainly of interest to the laboratory to
further define what step kinase activity regulates
whether it is transport, proteolysis, or turnover, in
future studies.
On the other hand, p38 MAP kinase but not Src
family inhibition attenuated an increase in secreted
levels of collagen-stimulated release of IL-1b.T h i sd a t a
s u p p o r t st h ei d e at h a tad i v e r g e n c ei nt h es i g n a l i n g
response occurs downstream of the membrane proximal
tyrosine kinase activity allowing for discreet regulation
of transcriptional and secretory events. Conversely, b
secretase but not g secretase inhibition significantly
increased release of IL-1b during collagen stimulation.
One interpretation of this result is that Ab1-40 or some
other proteolytic fragment of APP normally acts in an
autocrine fashion during collagen stimulation to down-
regulate the magnitude of proinflammatory activation.
However, since tyrosine kinase inhibition had no effect
on decreasing IL-1b secretion, yet was able to decrease
Ab1-40 release, it is reasonable to assume that a proteo-
lytic fragment generated after b secretase activity yet
before g secretase activity is involved in downregulating
cytokine release. This is in agreement with prior litera-
ture demonstrating that exosome secretion of C-term-
inal fragments of APP can occur in vitro suggesting that
they may have functions unique from Ab or APP
[62,63]. Indeed, several studies both in vitro and in vivo
have demonstrated that elevations in specific C-terminal
fragments, rather than Ab peptides, mediate cellular
death and behavioral dysfunction [64-66]. Tyrosine
kinase associated changes have also been linked to
unique APP C-terminal fragments, as well. For example,
the C99 but not the C89 fragment of APP, upon tyro-
sine phosphorylation, associates with the adaptor pro-
tein, ShcA, to likely propagate a unique signaling
response [67].
Although we have not yet determined the conse-
quences of increased monocytic Ab1-40 secretion fol-
lowing adhesion-stimulated release, there are several
possibilities. The secreted peptide could act upon plate-
lets to increase their aggregation [52], stimulate death
of endothelium [68] or increase endothelial proin-
flammatory protein expression to facilitate monocyte
transmigration [22,69]. The secreted peptide could also
act in an autocrine fashion to stimulate monocytic phe-
notype changes favoring increased recruitment to the
endothelium and subsequent adhesion [70]. This may
have some significance with respect to AD pathology as
the peptide is able to cross into the brain via interaction
with the receptor for advanced glycation end products
(RAGE) [71,72], but also may be important in regards to
the vascular deposition of Ab that is also evident in
AD [73].
During periods of acute or prolonged peripheral
inflammation when there is increased transendothelial
migration of monocytes and increased monocytic inter-
action with extracellular matrix components, this adhe-
sion may specifically perpetuate the inflammatory state
by stimulating APP-dependent proinflammatory signal-
ing in the monocytes and secretion of proinflammatory
molecules such as IL-1b and Ab1-40. Indeed, increased
monocytic cell surface APP is associated with HIV-asso-
ciated cognitive impairme n t[ 3 6 ] )a n dA l z h e i m e r ’sd i s -
ease [35] and cytokine and endotoxin stimulation [35].
Prior studies have reported that monocyte to macro-
phage differentiation correlates with increased expres-
sion of APP [74] consistent with our observations that
adhesion dependent activation of monocytes involves
APP-integrin dependent signaling. Indeed, others have
proposed a similar idea of an APP-related role in phago-
cyte activation by demonstrating increased expression of
gamma secretase components, presenilin and nicastrin,
in microglia during the gliotic response after brain
injury [75].
Conclusions
These data suggest that APP has a particular role in reg-
ulating monocyte/macrophage immune cell phenotype
in response to specific integrin-mediated stimulation. In
addition, these findings support the hypothesis that
monocyte/macrophage APP may contribute to adhe-
sion-dependent inflammatory changes in both the brain
and periphery in varying conditions including Alzhei-
mer’s disease, cardiovascular/cerebrovascular disease,
and vascular amyloidosis
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